TAK Overview

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.09T USD, increased 3.91

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to -15.40 USD, decreased -76.42

Takeda Pharmaceutical Co Ltd (TAK) has 47455 emplpoyees as of June 01 2026.

Today TAK has the market capitalization of 50.43B USD.